Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC")
CASTRES, France, June 16, 2025 /CNW/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs.
View PDF
PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients.
NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography. [1], [2], [3]
"With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs." said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.
About Pierre Fabre Laboratories
Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care.
[1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016
[2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015
[3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
17 minutes ago
- Cision Canada
Sprott Physical Uranium Trust Announces Upsized US$200 Million Bought Deal Financing
TORONTO, /CNW/ - Sprott Inc. (NYSE: SII) (TSX: SII) (" Sprott") on behalf of the Sprott Physical Uranium Trust (TSX: (TSX: U.U) (" SPUT" or the " Trust") is pleased to announce that as a result of strong investor demand, the Trust has amended its agreement with Canaccord Genuity Corp. (the " Underwriter"), pursuant to which the Underwriter has agreed to purchase 11,600,000 units of the Trust (the " Units") at a price of US$17.25 per Unit (the " Offering Price") for aggregate gross proceeds of US$200,100,000 (the " Offering"). The net proceeds per Unit to be received by the Trust will be not less than 100% of the most recently calculated net asset value of the Trust per Unit prior to the determination of the pricing of the Offering. The net proceeds of the Offering will be used by the Trust to acquire physical uranium in the form of uranium oxide in concentrates and uranium hexaflouride and related fees and expenses in accordance with the Trust's objective and subject to the Trust's investment and operating restrictions. Closing of the Offering is expected to occur on or about June 20, 2025 (the " Closing Date"), and is subject to regulatory approval including that of the Toronto Stock Exchange. The Offering will be made: (i) in all of the provinces and territories of Canada (other than Quebec) by way of a prospectus supplement to the Trust's existing base shelf prospectus dated January 3, 2024 (the " Base Shelf Prospectus"), as supplemented by a prospectus supplement (the " Prospectus Supplement" and together with the Base Shelf Prospectus, the " Offering Documents") pursuant to National Instrument 44-101 – Short-Form Prospectus Distributions and National Instrument 44-102 – Shelf Distributions; (ii) in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the " U.S. Securities Act") and any applicable securities laws of any state of the United States, to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act; and (iii) in jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction. The completion of the Offering shall be subject to the receipt of all necessary regulatory approvals and other conditions listed herein. The Offering Documents will be available at Investors should read the Offering Documents and other documents the Trust has filed for more complete information about the Trust and the Offering. This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The Units have not been and will not be registered under the U.S. Securities Act, or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. About Sprott Sprott is a global asset manager focused on precious metals and critical materials investments. We are specialists. We believe our in-depth knowledge, experience and relationships separate us from the generalists. Our investment strategies include Exchange Listed Products, Managed Equities and Private Strategies. Sprott has offices in Toronto, New York, Connecticut and California and the company's common shares are listed on the New York Stock Exchange and the Toronto Stock Exchange under the symbol "SII". For more information, please visit About the Trust Important information about the Trust, including its investment objectives and strategies, applicable management fees, and expenses, can be found on its website at Commissions, management fees, or other charges and expenses may be associated with investing in the Trust. The performance of the Trust is not guaranteed, its value changes frequently and past performance is not an indication of future results. Caution Regarding Forward-Looking Information This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities laws (" forward-looking statements"). Forward-looking statements in this press release include, without limitation, statements regarding the Offering, including the intended use of proceeds from any sale of Units and the timing and ability of the Trust to obtain all necessary approvals in connection with the Offering. With respect to the forward-looking statements contained in this press release, the Trust has made numerous assumptions regarding, among other things: investor demand the uranium market. While the Trust considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause the Trust's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing the Trust appears in the Offering Documents, each as updated by the Trust's continuous disclosure filings, which are available at All forward-looking statements herein are qualified in their entirety by this cautionary statement, and the Trust disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Cision Canada
17 minutes ago
- Cision Canada
VR Vision and Meta to Host Exclusive Webinar on VR Training Costs for Enterprises
TORONTO, June 16, 2025 /CNW/ - VR Vision, a global leader in enterprise XR training, is excited to announce a collaborative webinar with Meta titled "What Does VR Training Actually Cost? A Clear-Cut Guide to Your Investment." The event will take place on July 7, 2025, at 12:00 PM EST and will provide a transparent breakdown of the key cost factors involved in adopting VR training at scale. This exclusive session is designed for enterprise leaders, L&D professionals, and innovation teams looking to understand the true cost-benefit equation of immersive learning technology. As companies pivot toward immersive solutions for workforce development, VR Vision and Meta will unpack real-world pricing models, ROI benchmarks, and how organizations are scaling effective VR programs using platforms like Meta Horizon Managed Solutions and VR Vision's Vision Portal. Attendees will gain exclusive insights into: Total VR Training Investment Breakdown: From hardware and software to deployment and ongoing support. SaaS Pricing Models: Including options for Vision Portal licensing, pre-built modules, and ongoing maintenance. Real-World Case Studies: How global leaders like Toyota, Siemens, and Coca-Cola are reducing training costs and improving safety with VR. Live Q&A With Experts: Direct access to immersive training experts from both VR Vision and Meta. "Organizations are hungry for clarity when it comes to investing in VR," said Roni Cerga, Co-Founder & CEO of VR Vision. "This webinar is designed to strip away the guesswork and provide decision-makers with a crystal-clear roadmap to cost-efficient VR training deployments." Why Attend This event is free to attend but space is limited. SOURCE VR Vision Inc.
Cision Canada
17 minutes ago
- Cision Canada
Desjardins announces June and second quarter of 2025 cash distributions for some ETFs Français
MONTREAL, June 16, 2025 /CNW/ - Desjardins Investment Inc. (DI), acting as manager for Desjardins Exchange Traded Funds (ETFs), today announced the June and second quarter of 2025 cash distributions for some Desjardins ETFs listed on the TSX that pay a monthly or quarterly distribution. Unitholders of record on June 23, 2025, will receive cash distributions payable for these ETFs on June 30, 2025. Here is the list of the Desjardins ETFs that will pay cash distributions for June or second quarter of 2025, as well as the distribution amount per unit to be paid: Exchange Traded Funds (ETF) Ticker symbols (TSX) Distribution per unit ($) Desjardins Canadian Fixed Income ETFs Desjardins Canadian Universe Bond Index ETF DCU 0.0458 Desjardins Canadian Short Term Bond Index ETF DCS 0.0473 Desjardins 1-5 year Laddered Canadian Corporate Bond Index ETF DCC 0.0527 Desjardins 1-5 year Laddered Canadian Government Bond Index ETF DCG 0.0401 Desjardins Canadian Corporate Bond Index ETF DCBC 0.0636 Desjardins Canadian Preferred Share ETF Desjardins Canadian Preferred Share Index ETF DCP 0.0846 Desjardins Equity Index ETFs Desjardins Canadian Equity Index ETF DMEC 0.1466 Desjardins American Equity Index ETF DMEU 0.0569 Desjardins International Equity Index ETF DMEI 0.2867 Desjardins Emerging Market Equity Index ETF DMEE 0.1500 Desjardins Multifactor Net-Zero Emissions Pathway ETF Desjardins RI Canada Multifactor - Net-Zero Emissions Pathway ETF DRFC 0.2406 Desjardins RI USA Multifactor - Net-Zero Emissions Pathway ETF DRFU 0.0000 Desjardins RI Developed ex-USA ex-Canada Multifactor - Net-Zero Emissions Pathway ETF DRFD 0.4534 Desjardins RI Emerging Markets Multifactor - Net-Zero Emissions Pathway ETF DRFE 0.2165 Desjardins Net-Zero Emissions Pathway ETF Desjardins RI Canada - Net-Zero Emissions Pathway ETF DRMC 0.2121 Desjardins RI USA - Net-Zero Emissions Pathway ETF DRMU 0.0915 Desjardins RI Developed ex-USA ex-Canada - Net-Zero Emissions Pathway ETF DRMD 0.0000 Desjardins RI Emerging Markets - Net-Zero Emissions Pathway ETF DRME 0.1719 Desjardins Multifactor Low Fossil Fuel ETF Desjardins RI Global Multifactor - Fossil Fuel Reserves Free ETF DRFG 0.2474 Desjardins Active ETF Desjardins RI Active Canadian Bond - Net-Zero Emissions Pathway ETF DRCU 0.0554 Desjardins SocieTerra ETF Desjardins SocieTerra American Equity ETF DSAE 0.0088 Desjardins Alternative ETF Desjardins Market Neutral ETF DANC 0.0819 Desjardins Market Neutral ETF – US$ Hedged Units DANC.U 0.0000 1 Desjardins Absolute Return Global Equity Markets ETF – CA$ Hedged Units DAMG 0.0000 Desjardins Absolute Return Global Equity Markets ETF – US$ Hedged Units DAMG.U 0.0000 1 1 Denominated in U.S. dollar. For information about Desjardins ETFs, visit the manager's website at About Desjardins Group Desjardins Group is the largest cooperative financial group in North America and the sixth largest in the world, with assets of $487.9 billion as at March 31, 2025. It has been named one of the top employers in Canada by both Forbes magazine and Mediacorp. It has also been recognized as one of the World's Best Banks 2025 by Forbes. The organization has more than 56,100 skilled employees. To meet the diverse needs of its members and clients, Desjardins offers a full range of products and services to individuals and businesses through its extensive distribution network, its online platforms, and its subsidiaries across Canada. Ranked among the world's strongest banks according to The Banker magazine, Desjardins has one of the highest capital ratios and one of the highest credit ratings in the industry. In 2025, Desjardins Group is celebrating its 125th anniversary, marking more than a century of focusing its ambitions and expertise on being there for members and clients. About Desjardins Investments Inc. Desjardins Investments Inc., manager of the Desjardins Funds, is one of Canada's largest mutual fund manufacturers, with C$47.7 billion in assets under management as at March 31, 2025. DI offers a broad range of investment funds to Canadian investors and stands out in the industry, among others, through its world-renowned portfolio managers representing more than 20 asset management companies around the world. In addition, DI is one of the most committed actors in promoting and advancing responsible investment in Canada. Desjardins Exchange Traded Funds are not guaranteed, their value fluctuates frequently and their past performance is not indicative of their future returns. Commissions, management fees and expenses all may be associated with an investment in exchange traded funds. Please read the prospectus before investing. Desjardins Investment Inc. is the manager of the Desjardins Exchange Traded Funds. The Desjardins Exchange Traded Funds are offered by registered dealers.
